Hint mode is switched on Switch off
For swift navigation between sections

Biofarma
LEI 789000D0GNGY2XX9TL97

Organization name
Biofarma Ilac Sanayi ve Ticaret A.S.
Country name
Turkey
Country of registration
Turkey
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

Biofarma, founded in 1945 in Turkey, transitioned into a limited company in 1973 under the ownership of Mustafa Oncel. Relocating to Sancaktepe-Istanbul in 1990, it operates from a modern facility spanning 15,000 m2. Since 1998, it has been a joint-stock company and is currently part of the Isanne S.A.R.L. LUX. Group. Committed to trust, vision, mission, and traditional values, Biofarma aims to provide quality medicines to the Turkish market. Their vision is to become a globally recognized medical company, while their mission is to produce high-quality medicines meeting global standards and promoting social and environmental responsibility.

Awards

Documentation

Stocks

Public debt by currencies

Codes

  • LEI
    789000D0GNGY2XX9TL97
  • NACE
    *** ***
  • NAICS
    *** ***
Registration is required to get access.